Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma, Inc. is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens. The company has also explored additional applications of its LNC platform for delivering other therapeutics, including anti-infective and nucleic acid-based medicines.

Matinas BioPharma is headquartered in the United States and has focused its development activities on addressing significant unmet needs in infectious disease and drug delivery. Its programs remain subject to clinical development and regulatory review, and the company’s pipeline and priorities may change as research progresses.

Key Stats

• Today's Range: $2.70 to $2.87
• 50-Day Range: $2.40 to $4.52
• 52-Week Range: $2.26 to $28.95
• Volume: 35,267 shs
• Average Volume: 141,686 shs
• Market Capitalization: $2.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Matinas Biopharma Stock Analysis - MarketRank™

Matinas Biopharma scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas Biopharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas Biopharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas Biopharma has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.01% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently decreased by 87.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas Biopharma does not currently pay a dividend.

Dividend Growth

Matinas Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Matinas Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Matinas Biopharma this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for MTNB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of Matinas Biopharma is held by insiders.

Percentage Held by Institutions

11.77% of the stock of Matinas Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: matinasbiopharma.com
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 2
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -166.11%
• Return on Assets: -102.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 2.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.30 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 980,000
• Free Float: 935,000
• Market Cap: $2.81 million
• Optionable: N/A
• Beta: 2.08